Upregulation of Membrane-Bound CD40L on CD4+ T cells in Women with Primary Sjögren's Syndrome

Scandinavian Journal of Immunology

Volumn 79, Issue 1, 2014, Pages 37-42

  Belkhir, R ^a,b   Gestermann, N ^a   Koutero, M ^c   Seror, R ^b   Tost, J ^c   Mariette, X ^a,b   Miceli Richard, C ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c DIF   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; CD40 LIGAND; IONOMYCIN; MEMBRANE BOUND CD40 LIGAND; MESSENGER RNA; PHORBOL 13 ACETATE 12 MYRISTATE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DEREGULATION; DNA METHYLATION; ENHANCER REGION; EPIGENETICS; FEMALE; HUMAN; HUMAN CELL; MIDDLE AGED; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PYROSEQUENCING; SJOEGREN SYNDROME; UPREGULATION; VERY ELDERLY; X CHROMOSOME INACTIVATION;

EID: 84890891041     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12121     Document Type: Article

References (16)

1. McGrath H Jr. Skewed X, chromosome inactivation in scleroderma: comment on the article by Ozbalkan et al. Arthritis Rheum 2005;52:3679. author reply 3679-80.
2. Lu Q, Wu A, Tesmer L et al. Demethylation of CD40LG on the inactive X in T cells from women with lupus. J Immunol 2007;179:6352-8.
3. + T cells from women with systemic sclerosis: a possible explanation for female susceptibility. Arthritis Rheum 2012;64:2338-45.
4. Goules A, Tzioufas AG, Manousakis MN et al. Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases. J Autoimmun 2006;26:165-71.
5. Sellam J, Proulle V, Jüngel A et al. Increased levels of circulating microparticles in primary Sjögren's syndrome, systemic lupus erythematosus and rheumatoid arthritis and relation with disease activity. Arthritis Res Ther 2009;11:R156.
6. Van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000;67:2-17.
7. Vitali C, Bombardieri S, Jonsson R et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
8. Seror R, Ravaud P, Bowman SJ et al. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis 2010;69:1103-9.
9. Tost J, Gut IG. DNA methylation analysis by pyrosequencing. Nat Protoc 2007;2:2265-75.
10. Li G, Diogo D, Wu D et al. Human genetics in rheumatoid arthritis guides a high-throughput drug screen of the CD40 signaling pathway. PLoS Genet 2013;9:e1003487.
11. Kato K, Santana-Sahagún E, Rassenti LZ et al. The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J Clin Invest 1999;104:947-55.
12. Vakkalanka RK, Woo C, Kirou KA et al. Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera. Arthritis Rheum 1999;42:871-81.
13. Desai-Mehta A, Lu L, Ramsey-Goldman R et al. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996;97:2063-73.
14. Koshy M, Berger D, Crow MK. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 1996;98:826-37.
15. Tang Y, Luo X, Cui H et al. MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum 2009;60:1065-75.
16. Chen T, Li Z, Jing T et al. MicroRNA-146a regulates the maturation process and pro-inflammatory cytokine secretion by targeting CD40L in oxLDL-stimulated dendritic cells. FEBS Lett 2011;585:567-73.